Rapport Therapeutics Director Buys $9.5 Million in Company Stock By Investing.com
James Healy, Director of Rapport Therapeutics, Inc. (NASDAQ:RAPP), recently purchased a significant…
James Healy, Director of Rapport Therapeutics, Inc. (NASDAQ:RAPP), recently purchased a significant…
